Limiting the IPRs of Pharmaceutical Companies Through EU Competition Law: The First Crack in the Wall

Scripted - Journal of Law, Technology & Society, Vol. 8, No. 1, pp. 93-98, April 2011

7 Pages Posted: 28 Oct 2011

Date Written: April 1, 2011

Abstract

The exclusivity granted to pharmaceutical companies through intellectual property rights (IPRs) may in certain circumstances run counter to the main objectives for which these rights are intended. EU competition law has stepped in to correct systemic failures that have adversely affected the competitiveness of the sector and the public interest of individuals in access to improved and affordable medicines. In the case of AstraZeneca v Commission, the General Court of the European Union found, for the first time, that a pharmaceutical company had abused its dominant position by (mis)using regulatory patent procedures to eliminate or restrict the market entry of competitors of generic medicines. To understand the way by which EU competition law intersects with IPRs and safeguards (patent regulations) requires an appreciation of the tensions (Part I) that underlie the expansive application of competition rules in the pharmaceutical sector (Parts II, III) as well as of the new policies that have emerged (Part IV).

Suggested Citation

Xenos, Dimitris, Limiting the IPRs of Pharmaceutical Companies Through EU Competition Law: The First Crack in the Wall (April 1, 2011). Scripted - Journal of Law, Technology & Society, Vol. 8, No. 1, pp. 93-98, April 2011 . Available at SSRN: https://ssrn.com/abstract=1950336

Dimitris Xenos (Contact Author)

University of Suffolk ( email )

Waterfront Building
19 Neptune Quay
Ipswich, IP4 1QJ
United Kingdom
+44(0)14733-38483 (Phone)

HOME PAGE: http:// https://www.uos.ac.uk/people/dimitris-xenos

Register to save articles to
your library

Register

Paper statistics

Downloads
327
rank
88,381
Abstract Views
732
PlumX Metrics